两种方案治疗慢性乙型肝炎肝纤维化的成本-效果分析  

Cost-effectiveness Analysis of Two Regimens in the Treatment of Chronic Hepatitis B Fibrosis

作　　者：王沛陵[1] 李晶莹[1] 付娜[1] 段小宛 

机构地区：[1]首都医科大学附属北京佑安医院,北京100069

出　　处：《中国药房》2015年第35期4899-4901,共3页China Pharmacy

摘　　要：目的:评价两种治疗慢性乙型肝炎肝纤维化方案的成本-效果。方法:选择112例慢性乙型肝炎肝纤维化患者随机分成复方鳖甲软肝片组(A组)和安络化纤丸组(B组)各56例,两组患者分别服用恩替卡韦分散片联合相应的中成药。分别在治疗前后检测两组患者的肝纤维化指标、瞬时弹性成像,进行中医证候评分,计算有效率,比较两种方案的成本-效果。结果:A组方案的成本为9 227.10元,有效率为74.11%,成本-效果比为12 451;B组方案的成本为8 202.90元,有效率为69.28%,成本-效果比为11 840;增量成本-效果比为21 205。B组方案具有较好的成本-效果。敏感度分析结果与成本-效果分析结果一致。结论:安络化纤丸联合恩替卡韦治疗慢性乙型肝炎肝纤维化的成本-效果优于复方鳖甲软肝片联合恩替卡韦。OBJECTIVE：To analyze the cost-effectiveness of two regimens in the treatment of chronic hepatitis B fibrosis.METHODS：112 cases of chronic hepatitis B fibrosis were divided into Compound biejia ruangan tablet group（group A,n=56）and Anluo huaxian pill group（group B,n=56）. Both groups received Entecavir dispersible tablets combined with relevant Chinese patent medicine. The liver fibrosis index and transient elastography of 2 group were detected before and after treatment,TCM symptom score and effective rate calculation were conducted to compare the cost-effectiveness of 2 groups. RESULTS：The cost,effective rate and cost-effectiveness ratio of group A were 9 227.10 yuan,74.11% and 12 451;those of group B were 8 202.90 yuan,69.28% and 11 840;incremental cost-effectiveness ratio was 21 205. Group B showed a better cost-effectiveness. Result of sensitivity test was same to that of cost-effectiveness analysis. CONCLUSIONS：The cost-effectiveness of Anluo huaxian pill combined with Entecavir dispersible tables is better than Compound biejia ruangan tablet combined with Entecavir dispersible tables in the treatment of chronic hepatitis B fibrosis.

关 键 词：复方鳖甲软肝片 安络化纤丸 乙型肝炎肝纤维化 成本-效果分析 

分 类 号：F407.7[经济管理—产业经济] R932[医药卫生—生药学]